<SEC-DOCUMENT>0001564590-21-006189.txt : 20210217
<SEC-HEADER>0001564590-21-006189.hdr.sgml : 20210217
<ACCEPTANCE-DATETIME>20210217064138
ACCESSION NUMBER:		0001564590-21-006189
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20210217
FILED AS OF DATE:		20210217
DATE AS OF CHANGE:		20210217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		21642596

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20210216.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20210216.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:20pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:20pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="giwyawa45ad5000001.jpg" title="" alt="" style="width:169px;height:0px;"><br /><font style="font-weight:bold;">FORM 6-K</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="giwyawa45ad5000002.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNDER THE SECURITIES EXCHANGE ACT OF 1934<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF FEBRUARY 2021<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="giwyawa45ad5000003.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Translation of registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Address of principal executive offices)</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="giwyawa45ad5000004.jpg" title="" alt="" style="width:169px;height:0px;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F:<font style="color:#000000;"> </font>Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746;</font> Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1):<font style="color:#000000;"> </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)<font style="color:#000000;">: </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 17, 2021, BioNTech SE (the &#8220;Company&#8221;) and Pfizer Inc. announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, the companies&#8217; COVID-19 Vaccine, to the 27 European Union (EU) member states. The press release is attached hereto as Exhibit 99.1.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">SIGNATURE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<font style="color:#000000;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.63%;"></td>
<td style="width:4.63%;"></td>
<td style="width:44.73%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 17, 2021 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">EXHIBIT INDEX </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:10.98%;"></td>
<td style="width:89.02%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Exhibit</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex991_40.htm"><font style="text-decoration:underline;">Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY&#174;.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_40.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_40.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.94%;"></td>
<td style="width:49.94%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0fixzd3tdx000001.jpg" title="" alt="" style="width:169px;height:67px;"></p></td>
<td valign="middle" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0fixzd3tdx000002.jpg" title="" alt="" style="width:240px;height:26px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer and BioNTech to Supply the European Union with 200 Million <br />Additional Doses of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">New agreement brings total supply to the European Union to 500 million doses, with delivery expected by the end of 2021</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">European Commission has the option to request an additional 100 million doses</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NEW YORK and MAINZ, GERMANY, February 17, 2021 (GLOBE NEWSWIRE) <font style="font-weight:normal;">&#8212; Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, the companies&#8217; COVID-19 vaccine, to the 27 European Union (EU) member states. The EC has the option to request supply of an additional 100 million doses. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This new agreement is in addition to the 300 million doses that have already been committed to the EU through 2021 under the first <font style="text-decoration:underline;">supply agreement</font> signed last year. The additional 200 million doses are expected to be delivered in 2021, with an estimated 75 million to be supplied in the second quarter.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of doses to be delivered to the EU member states by the end of 2021 is now 500 million, with the potential to increase to 600 million based on the option granted in the new agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We recognize that more people must be vaccinated as soon as possible to help defeat this virus and control the global pandemic. We are working relentlessly to support the further roll-out of vaccination campaigns in Europe and worldwide by expanding manufacturing capacity,&#8221; said <font style="font-weight:bold;">Albert Bourla, Chairman and Chief Executive Officer, Pfizer. </font>&#8220;With this new agreement with the European Commission, we now expect to deliver enough doses to vaccinate at least 250 million Europeans before the end of the year.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Broad access to well-tolerated and highly efficacious vaccines is essential to halt the pandemic. We have taken additional steps to expand our manufacturing capacity to two billion doses in 2021,&#8221; said <font style="font-weight:bold;">Ugur Sahin, M.D., CEO and Co-founder of BioNTech.</font> &#8220;We will initiate production at our Marburg facility this month and have strengthened our manufacturing network with additional partners. We are continuing to evaluate, together with governments, authorities and partners at all levels, how we might address an even higher future supply requirement for our vaccines.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMIRNATY is being produced in BioNTech&#8217;s and Pfizer&#8217;s manufacturing sites in Europe. The distribution of COMIRNATY by the EU member states will continue to be determined according to the populations identified in EU and national guidance. Globally, Pfizer and BioNTech aim to manufacture approximately two billion doses in total by the end of 2021, assuming continuous process improvements, expansion at current facilities, adding new suppliers and contract manufacturers and updated six-dose labeling.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the EU, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">AUTHORIZED USE IN THE EU: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> &#9660;<font style="font-weight:normal;"> (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorisation by the European Medicines Agency to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. The European Medicines Agency&#8217;s (EMA&#8217;s) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT SAFETY INFORMATION: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> may be lower in immunosuppressed individuals.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">As with any vaccine, vaccination with COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (&gt; 80%), fatigue (&gt; 60%), headache (&gt; 50%), myalgia and chills (&gt; 30%), arthralgia (&gt; 20%), pyrexia and injection site swelling (&gt; 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">There is limited experience with use of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in pregnant women. Administration of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">It is unknown whether COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is excreted in human milk. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">Interactions with other medicinal products or concomitant administration of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> with other vaccines has not been studied. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:3.97%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For complete information on the safety of COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The black equilateral triangle denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to <font style="text-decoration:underline;">EudraVigilance</font> or directly to BioNTech using email <font style="text-decoration:underline;">medinfo@biontech.de</font>, telephone&#160;+49 6131 9084 0, or via the website&#160;<font style="text-decoration:underline;">www.biontech.de</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Pfizer: Breakthroughs That Change Patients&#8217; Lives</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <font style="text-decoration:underline;">www.Pfizer.com</font>. In addition, to learn more, please visit us on <font style="text-decoration:underline;">www.Pfizer.com</font> and follow us on Twitter at <font style="text-decoration:underline;">@Pfizer</font> and <font style="text-decoration:underline;">@Pfizer News</font>, <font style="text-decoration:underline;">LinkedIn</font>, <font style="text-decoration:underline;">YouTube</font> and like us on Facebook at <font style="text-decoration:underline;">Facebook.com/Pfizer</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Disclosure Notice:&#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information contained in this release is as of February 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This release contains forward-looking information about Pfizer&#8217;s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative assessments of available data, potential benefits, expectations for clinical trials, supply agreements with the EC and the timing of delivery of doses thereunder, the anticipated timing of regulatory submissions, regulatory approval or authorization and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the in vitro and Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations upon commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S.) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine&#8217;s benefits outweigh its known risks and determination of the vaccine&#8217;s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine&#8217;s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer&#8217;s business, operations and financial results; and competitive developments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10 -Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities &#160;and Exchange Commission and available at&#160;<font style="text-decoration:underline;">www.sec.gov</font>&#160;and&#160;<font style="text-decoration:underline;">www.pfizer.com.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About BioNTech</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <font style="text-decoration:underline;">www.BioNTech.de</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Forward-looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech&#8217;s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer regarding a COVID-19 vaccine; the ability of BNT162b2 to prevent COVID-19 caused by new virus variants; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan for BNT162b2 (COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimate for 2021 and beyond as well as the timing and expectations of manufacturing capacities of the manufacturing network; discussions with government, regulatory authorities and partners to address future vaccine demand. Any forward-looking statements in this press release are based on BioNTech&#8217;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for COVID-19; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Widger</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+44 1737 330909</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Andrew.Widger@Pfizer.com</font> <br /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chuck Triano</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (212) 733-3901</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Charles.E.Triano@Pfizer.com</font>&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jasmina Alatovic</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 6131 9084-1513</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Media@biontech.de</font>&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sylke Maas, Ph.D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1074</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Investors@biontech.de</font> </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>giwyawa45ad5000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 giwyawa45ad5000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y_HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8/V<?\ DH>H?]@J
/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>giwyawa45ad5000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 giwyawa45ad5000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gu0fixzd3tdx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0fixzd3tdx000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 A(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]CT/UKULPR^ECJ6WO6T?]="(3<6?;=8'C?6/[!\%:OJ0;;)%;,(S_MM\J_\
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M.RD\G\!DU]IQHL4:QHH5$ 50.P%</$]>T(45UU_1?J516['4445\>= 4444
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M4PVY)[EO+/\ L#Y4_P#'0*PZ^QO^$"\(_P#0M:5_X")_A1_P@7A'_H6M*_\
M 1/\*^QI\28>G!0C3=EIT.=T6^IX[^SYH_GZ[J>L.ORVL @C)_O.<G'T"_\
MCU>E_$SQ_#X)T3; ROJUTI%M$>=GK(P]!V]3^-=7IFC:9HL#PZ786UG$[;V2
MWB"!CTR<=ZK:AX5\/ZM=FZU'1K&[N" IEG@5VP.@R17B8C'4<3C?K%:+<>WH
M:J+4;(^,[BXFN[F6YN)6EFE<O)(YR68G))-15]C?\(%X1_Z%K2O_  $3_"C_
M (0+PC_T+6E?^ B?X5[JXFH+14W^!E[%]SXYHK[&_P"$"\(_]"UI7_@(G^%'
M_"!>$?\ H6M*_P# 1/\ "C_6>C_(_P  ]B^Y\<T5]C?\(%X1_P"A:TK_ ,!$
M_P */^$"\(_]"UI7_@(G^%'^L]'^1_@'L7W,'X,Z1_97PXLY&7;+?.]TWT)P
MO_CJ@_C73^)_#.G>+=$FTO4HR8W^9)%^]$XZ,I]1_P#6K5MX(;6WCM[>)(H8
ME"1QH,*J@8  ["I*^5K8F<\0Z\79MW]#=*RL?(WC'X<:]X.N'-S;M<6&?DO8
M5)0C_:_NGV/X$UR%?<[*&4JP!4C!!'!KD]5^&7@W6':2YT*W21N2]OF$Y]?D
M(!KZ3"\36CRXB.O=?Y&,J/8^28+FXM7WV\\L+_WHW*G]*?<WUW>'-U=3SX_Y
MZR%OYU]*O\"O!C-E5OT'HMQQ^HJ]8_!OP18N'.E-<L.AN)W8?ED#]*[)<18)
M>\HMOT7^9/LI'S#IFD:CK5XMIIEE/=SM_!$A;'N?0>YKZA^%/A;6?"7A9['6
M)HB\DQFC@0[O)R!D%NAY&>..O)S786&FV.EVXM]/L[>UA'2.",(/R%6J\+,\
MZGC(>RC&T?O9K"GRZGR+\3M8_MOXB:O<*VZ**7[/'Z;8_EX^I!/XUR-?8[>!
M/";NSOX;TMF8Y)-JF2?RI/\ A O"/_0M:5_X")_A7IT>(L/2IQIJ#LDET(=)
MMWN>%_ C1OM_CF34'7,>GV[.#Z._RC]"WY5]+5G:7H.D:()1I6FVEEYN/,^S
MQ!-V,XSCKU/YUHUX&9XWZ[B/:I65K(TA'E5@HHHKSRPHHHH **** "BBB@ H
MHHH KWMC::E:26E];17-O(,/%*@93^!KR3Q5\!=.O2]SX<NC8S'G[-.2\1^C
M?>7]:]CHKJPN-KX65Z,K?E]Q,HJ6Y\;>(?!?B#PM*5U;39HH\X6=1NB;Z,./
MPZU@5]S21I-&T<J*Z,,,K#((]Q7G_B+X->$]=WRP6S:9<MSYEGPI/NA^7\L5
M]-A>)8/W<1&WFO\ +_AS&5%]#Y9HKU'7_@7XFTS=)ICP:K .@C/ER8_W6X_(
MFO.=0TN_TFX-OJ-E<6DP_@GC*']:^AP^,H8A7I33_/[MS)Q:W*E%%%=(@HHH
MH **** "BBB@ KV;]GS1O.UK5-9=?EMH5@C)_O.<G'T"_P#CU>,U]3_!C1O[
M)^'-I*RXEOG:Z;Z'A?\ QU0?QKQ<_K^RP3BMY:?YFE)7D>@T445^?G4%%%%
M!1110 4444 %%%% !1110 4444 >,?M!ZSY.C:7HR-\UQ,UQ(!_=08&?J6/_
M 'S7S]7?_&76?[6^(U[&K;HK%%M4^J\M_P"/,P_"N K]'R>A['!PCU>OWG)4
M=Y%BPLY=1U&UL8!F:YE6%!_M,0!_.OMBPLXM.TZVL8!B&VB6)!Z*H '\J^8?
M@OHW]K?$:TE9=T5A&]T_U'RK_P"/,#^%?4U?/<35^:M"BNBO]_\ PQK16EPH
MHHKYDV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gu0fixzd3tdx000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0fixzd3tdx000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 NX# 2(  A$! Q$!_\0
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M_2?]\FNS^S,7_)^*_P Q71@9/K1D^M;_ /PBLO\ S])_WR:/^$5E_P"?I/\
MODT?V9B_Y/Q7^871G:,3_;%MS_%_0UW-8%CX>DM+V*<W",$.<!3S6_7OY3AZ
ME"DXU%9W_0ELY_QOQX.U#'HG_H:UXQN;U/YU[KK^F-K&B7-@D@C:8+AV&0,,
M#_2N&_X5?=?]!.'_ +]G_&O39YF,H5*DTXKH<'N;U/YT;F]3^==Y_P *ONO^
M@G#_ -^S_C1_PJ^Z_P"@G#_W[/\ C18Y/JE;^4X/<WJ?SHW-ZG\Z[S_A5]U_
MT$X?^_9_QH_X5?=?]!.'_OV?\:+!]4K?RG![F]3^=&YO4_G7>?\ "K[K_H)P
M_P#?L_XT?\*ONO\ H)P_]^S_ (T6#ZI6_E.#W-ZG\Z].^&))TJ^R<_OQ_P"@
MUF_\*ONO^@G#_P!^S_C75^%/#LGAVTN()+A)C+('!52,<8H1TX7#U(55*2T.
M@HHHIGJ!6#K?B[2]#)CED,UR/^6,7)'U/05B>-O%[Z>6TO3GQ<D?OI1UC![#
MW]^W\O,68LQ9B2Q.23WI7.#$8SD?+#<['4/B/JUP2+..&T3L<;V_,\?I6!<>
M(M9NB3-J=T<]A(5'Y#BLY$:1PB*68G 51DFM^R\$Z]>J&%D84/\ %.P3].OZ
M4'!SUJKW;,-[B>0Y>:1C_M,34>YO4_G7;1?#+4V'[V]M$]EW-_05-_PK"[[Z
ME#_W[/\ C0/ZK6?V3@]S>I_.C<WJ?SKO/^%7W7_03A_[]G_&C_A5]U_T$X?^
M_9_QHL'U2M_*<'N;U/YT;F]3^==Y_P *ONO^@G#_ -^S_C1_PJ^Z_P"@G#_W
M[/\ C18/JE;^4X/<WJ?SKNOAB2=4OLDG]R/_ $*G?\*ONO\ H)P_]^S_ (UT
M'A3PE-X=N[B:2[282QA %0C'.:#;#X>K&JI26AU=%%%,]<**** "BBB@ HHH
MH **** "BBB@#PKQ"Q_X274^3_Q]2=_]HU7L&;SVY/W?7W%6/$7_ ",NJ?\
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MCV'L*UZ**9[<8J*M$****"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#PKQ%_R,NJ?]?4G_H1JOI_^O;_ '?ZBK'B+_D9=4_Z^I/_ $(U
M7T__ %[?[O\ 45)\]+^(_4Z8_$C6PQ'EV?7_ )YM_P#%4G_"R=;_ .>5D?\
MMFW_ ,57(-]X_6I;>TN;QBMM;S3LHR1$A8@?A3+^L5GM)G5_\+)UO_GC9?\
M?MO_ (JC_A9.M_\ /&R_[]M_\57.?V+JO_0,O/\ OPW^%']C:K_T#;S_ +\-
M_A0/VU?NSH_^%DZW_P \;+_OVW_Q5'_"R=;_ .>-E_W[;_XJN<_L;5?^@;>?
M]^&_PH_L;5?^@;>?]^&_PH#VU?NSH_\ A9.M_P#/&R_[]M_\51_PLG6_^>-E
M_P!^V_\ BJYS^QM5_P"@;>?]^&_PH_L;5?\ H&WG_?AO\* ]M7[LZ/\ X63K
M?_/&R_[]M_\ %5%/\1-=FC*(UM"3_%'%S^I-8/\ 8VJ_] V\_P"_#?X5'+IE
M_;QEYK&YC0=6>)@/U% .M7MNR&:::ZG:::1Y97.69CDDUU_A;P1<W\\=WJ43
M0V:G<(W&&E_#L*Y:PU&[TR<3V<QCD'? /\Z])\+^.TU.9+'4E2*Z;B.5>%D/
MH?0_SH*PT:4I_O'J=H %    '  I:**9[9X=XI_Y&G4O^N[5;\#?\CA8_P#
M_P#T!JJ>*?\ D:=2_P"N[5;\#?\ (X6/_ __ $!J1X,?]X7K^I[-7,^/I"GA
M&Z _C=%_\>!_I735RWQ!4GPE,?21#^M,]FO_  I>AY!7K?PY@$7A?S .99W8
M_A@?TKR2O7_AZX?PG$H_@E=3^>?ZTD>7@/XOR.IHHHIGLA1110 4444 %%%%
M 'E7Q*@$?B&"4#_6VXS]02/Y8KCXG,<J..JL"*[7XFN#K5G'W6WR?Q8_X5Q
MY('O2/!Q.E:5CZ&!W*".XS0WW&^E(@Q&H/8 4K?<;Z4/8]X\XKH/"O\ Q\7'
M^X/YUS]=!X5_X^+C_<'\Z^,RS_>X?UT+>QU%1S0QW$312H'1AR#4E%?9M)JS
M(.+U;1Y-/?S$R]N3PW=?8UEUZ.Z+(A1U#*PP01P:Y/6-#:TW3VP+0=2O=/\
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M4?\ "R-;_P">=G_W[;_XJN>_L35O^@7>_P#@._\ A1_8FK?] N]_\!W_ ,*
M]M7[LZ'_ (61K?\ SSL_^_;?_%4?\+(UO_GG9_\ ?MO_ (JN>_L35O\ H%WO
M_@._^%']B:M_T"[W_P !W_PH#VU?NSH?^%D:W_SSL_\ OVW_ ,51_P +(UO_
M )YV?_?MO_BJY[^Q-6_Z!=[_ . [_P"%']B:M_T"[W_P'?\ PH#VU?NSH?\
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MM=37 ?%#_CTTW_??^0H,,3)QI-HQO^%D:W_SSL_^_;?_ !5'_"R-;_YYV?\
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MT4"7JR#HWT]Z^?S'*KWJT%ZK_+_(I,PM-U.;3IMR?-&?OH3P?_KUVEI>0WL
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M^1IU+_KNU6_ W_(X6/\ P/\ ] :JGBG_ )&G4O\ KNU6_ W_ ".%C_P/_P!
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M5?<'_"%>'?\ H&)_W\?_ !H_X0KP[_T#$_[^/_C110'L:?\ *ON#_A"O#O\
MT#$_[^/_ (U>TW0=,TB5Y+"T6%W&UB&8Y'XFBB@:I03NDC1JCJ6CZ?JZQK?V
MPF6,DH"Q&,]>AHHH*:35F9W_  A7AW_H&)_W\?\ QK<AACMX(X8EVQQJ$1?0
M#@444"C",?A5A]%%%!04444 %%%% !1110!BS^$M"NKB2XFT]'EE8N[;VY)Y
<)ZTU/!V@1ME-.0'&/OO_ (T44&?LJ>_*ON/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>giwyawa45ad5000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 giwyawa45ad5000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>giwyawa45ad5000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 giwyawa45ad5000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ! A(# 2(  A$! Q$!_\0
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/3_T;%110!]/T444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
